Keyphrases
C.difficile Infection
100%
Clostridium Difficile Infection
100%
Orally Administered
100%
Nanoparticle Vaccine
100%
Difficile
66%
Mouse Model
50%
Antibiotics
33%
Microbiome
33%
Nanoparticles
33%
Antibody Response
33%
Diarrhea
16%
Vancomycin
16%
Anaerobic Organism
16%
Surface Proteins
16%
Polypeptide
16%
Intestine
16%
Antigen-specific
16%
Intraperitoneal Injection
16%
Bacterial Load
16%
Immunogenicity
16%
Receptor-binding Domain
16%
Pseudomembranous Colitis
16%
Spore-forming
16%
Clostridioides Difficile
16%
C. Difficile Toxin
16%
TcdB
16%
Poly-γ-glutamic Acid (γ-PGA)
16%
Chitosan
16%
IgG Antibody
16%
Metronidazole
16%
M Cells
16%
Hospital-acquired Infection
16%
Specific IgA
16%
IgA Antibody
16%
Fidaxomicin
16%
Serum IgE
16%
Protein Immunogenicity
16%
C. Difficile Toxin B
16%
Nanoparticle Delivery System
16%
Target-based Approach
16%
Complete Protection
16%
Oral Vaccine
16%
Asymptomatic Spread
16%
Cell Lining
16%
Medicine and Dentistry
Infection
100%
Clostridium Difficile Infection
100%
Nanoparticle
100%
Disease
50%
Antibiotics
33%
Microbiome
33%
Antibody Response
33%
Immunogenicity
33%
Diarrhea
16%
Vancomycin
16%
Symptom
16%
Amoxicillin
16%
Gut
16%
Side Effect
16%
Polypeptide
16%
Intestine
16%
Glutamic Acid
16%
Intraperitoneal Drug Administration
16%
Metronidazole
16%
Receptor Binding
16%
Chitosan
16%
Spore
16%
Fidaxomicin
16%
Antigen Specificity
16%
Pseudomembranous Colitis
16%
Microfold Cell
16%
Oral Vaccine
16%
Hospital Infection
16%
Immunoglobulin G Antibody
16%
Immunoglobulin A Antibody
16%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Nanoparticle
100%
Clostridium Difficile Infection
100%
Disease
50%
Mouse Model
50%
Antibiotic Agent
33%
Immunogenicity
33%
Microbiome
33%
Receptor
16%
Amoxicillin
16%
Diarrhea
16%
Vancomycin
16%
Symptom
16%
Glutamic Acid
16%
Polypeptide
16%
Side Effect
16%
Pseudomembranous Colitis
16%
Chitosan
16%
Metronidazole
16%
Anaerobe
16%
Immunoglobulin G Antibody
16%
Intraperitoneal Injection
16%
Hospital Infection
16%
Oral Vaccine
16%
Immunoglobulin A Antibody
16%
Fidaxomicin
16%